"An informative, non-repetitive meeting allowing interaction for participants. It was great to see all the current approaches that are being used to target RAS, by basis pharmaceutical industries!"

University Michigan

Past Attendee
University of Michigan

Past Attendee
The Beatson Institute


"Well organised, informative and good to meet fellow scientists"

"An enriching experience & a great opportunity to hear from the leaders in the RAS research & development field"


Past Attendee
SpringWorks Therapeutics

Past Attendee
Sanofi Genzyme



"Excellent overview of the current state of KRAS clinical and pre-clinical research"

"The meeting content successfully captured the latest goings on in the field, and brought together all the key players in a setting that encouraged interaction"


Past Attendee
Revolution Medicines


2020 Speaker - Channing Der
Sarah Graham Kenan Distinguished Professor
University of North Carolina at Chapel Hill


"I’m excited for networking with other researchers, hearing the most recent ideas and directions for targeting RAS, establishing new collaborations"

"The exciting results with G12C KRAS inhibitors have re-energized work to identify further strategies for developing new treatments. Combination approaches to RAS mutant cancers may be needed and I’m excited to see new developments in targeting RAS as well as combination approaches that may deliver new therapies for these cancers"

Bryan Smith Deciphera

2020 Speaker – Bryan Smith
VP Biological Sciences
Deciphera Pharmaceuticals

2020 Speaker - Julian Downward
Associate Research Director
Francis Crick Institute


Julian Downwar

"The field of RAS inhibitory drugs has exploded in the last few years and this meeting will be an excellent opportunity to catch up on the latest developments in this fast-moving area"

"The recent Ras Meeting in Boston was an exciting and educational opportunity bringing together basic and clinical scientists studying the Ras pathway and the clinical implications of the dysregulation of this pathway. Scientists presented their concepts on how they believe the pathway; until recently difficult to influence; can now be modulated. And how this progress has translated into clinical trials in various diseases driven by mutations of that pathway"

Steve Fruchtman formal

2020 Speaker - Steven Fruchtman
President & CEO

Onconova Therapeutics


2020 Speaker - Frank Haluska
President & CEO
Anchiano Therapeutics

Frank Haluska

"The RAS-Targeted Summit is a leading forum for publicizing and exchanging ideas about the therapeutic targeting of this crucial driver of malignancy. We look forward to seeing emerging data and presenting our contributions to the effort to develop treatments with broad patient impact"